Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy

Brazilian Journal of Medical and Biological Research

Volumn 42, Issue 5, 2009, Pages 445-452

  Moscoso Solorzano, G T ^a   Mastroianni Kirsztajn, G ^a   Ozaki, K S ^a   Franco, M F ^a   Pacheco Silva, A ^a   Câmara, Niel O S ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Kidney transplantation; Mycophenolate mofetil; Renal allograft survival; Renin angiotensin system

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG POTENTIATION; FEMALE; GRAFT SURVIVAL; HUMAN; KIDNEY BIOPSY; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; RENAL GRAFT DYSFUNCTION;

EID: 68249135377     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2009000500008     Document Type: Article

References (37)

1. Di Paolo S, Schena A, Stallone G, Grandaliano G, Soccio M, Cerullo G, et al. Captopril enhances transforming growth factor (TGF)-beta1 expression in peripheral blood mononuclear cells: a mechanism independent from angiotensin converting enzyme inhibition? A study in cyclosporine-treated kidney-transplanted patients. Transplantation 2002; 74: 1710-1715.
2. Szabo A, Lutz J, Schleimer K, Antus B, Hamar P, Philipp T, et al. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000; 57: 982-991.
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
4. Joosten SA, Sijpkens YW, van Kooten C, Paul LC. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 2005; 68: 1-13.
5. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996; 49: 518-524.
6. Tullius SG, Hancock WW, Heemann U, Azuma H, Tilney NL. Reversibility of chronic renal allograft rejection. Critical effect of time after transplantation suggests both host immune dependent and independent phases of progressive injury. Transplantation 1994; 58: 93-99.
7. Ma J, Matsusaka T, Yang H, Kawachi H, Shimizu F, Isaka Y, et al. Local actions of endogenous angiotensin II in injured glomeruli. J Am Soc Nephrol 2004; 15: 1268-1276.
8. Anderson PW, Zhang XY, Tian J, Correale JD, Xi XP, Yang D, et al. Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells. Kidney Int 1996; 50: 745-753.
9. Remuzzi A, Gagliardini E, Donadoni C, Fassi A, Sangalli F, Lepre MS, et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002; 62: 885-894.
10. Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000; 58: 2425-2436.
11. Remuzzi A, Fassi A, Bertani T, Perico N, Remuzzi G. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. Am J Kidney Dis 1999; 34: 626-632.
12. Adamczak M, Gross ML, Amann K, Ritz E. Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol 2004; 15: 3063-3072.
13. Ma LJ, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005; 16: 966-976.
14. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-296.
15. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000; 57: 1803-1817.
16. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001; 12: 2832-2837.
17. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000; 35: 695-707.
18. Noris M, Mister M, Pezzotta A, Azzollini N, Cassis P, Benigni A, et al. ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney Int 2003; 64: 2253-2261.
19. Remuzzi G, Perico N. Routine renin-angiotensin system blockade in renal transplantation? Curr Opin Nephrol Hypertens 2002; 11: 1-10.
20. Zaltzman JS, Nash M, Chiu R, Prasad R. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol Dial Transplant 2004; 19: 940-944.
21. Artz MA, Hilbrands LB, Borm G, Assmann KJ, Wetzels JF. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19: 2852-2857.
22. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-2409.
23. Kimball JA, Pescovitz MD, Book BK, Norman DJ. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995; 60: 1379-1383.
24. Merville P, Berge F, Deminiere C, Morel D, Chong G, Durand D, et al. Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant 2004; 4: 1769-1775.
25. Srinivas TR, Kaplan B, Schold JD, Meier-Kriesche HU. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation 2005; 80: S211-S220.
26. Weir MR, Fink JC, Hanes DS, Gardner J, Klassen DK, Cangro C, et al. Chronic allograft nephropathy: effect of cyclosporine reduction and addition of mycophenolate mofetil on progression of renal disease. Transplant Proc 1999; 31: 1286-1287.
27. Gonzalez Molina M, Seron D, Garcia del Moral R, Carrera M, Sola E, Jesus Alferez M, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004; 77: 215-220.
28. Yang CW, Ahn HJ, Kim WY, Li C, Jung JY, Yoon SA, et al. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation 2003; 75: 309-315.
29. Noris M, Azzollini N, Pezzotta A, Mister M, Benigni A, Marchetti G, et al. Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. J Am Soc Nephrol 2001; 12: 1937-1946.
30. Rodriguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincon J, Chavez M, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 2001; 59: 2222-2232.
31. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
32. Isoniemi H, Taskinen E, Hayry P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 1994; 58: 1195-1198.
33. Remuzzi G, Ruggenenti P. Overview of randomised trials of ACE inhibitors. Lancet 2006; 368: 555-556.
34. Opelz G, Zeier M, Laux G, Morath C, Dohler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257-3262.
35. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889-899.
36. Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003; 63: 209-216.
37. Fujihara CK, Avancini Costa Malheiros DM, De Nucci G, Zatz R. Mycophenolate mofetil reduces renal injury in the chronic nitric oxide synthase inhibition model. Hypertension 2001; 37: 170-175.